In our study, we aimed to evaluate the prognostic role of the hemoglobin–albumin–lymphocyte–platelet (HALP) score, which is a composite marker reflecting both inflammatory and nutritional status, in patients with metastatic NSCLC receiving immunotherapy. The gene discussed is ALB; the disease is non-small cell lung carcinoma.